Malignant transformation of endometriosis is a rare, documented complication of endometriosis. Endometriosis shares characteristics with malignancy and has biological systems central to its progression and malignant transformation. Evidence has emerged on the role of the fallopian tube in endometriosis and ovarian cancer. This has led to a paradigm shift in how the fallopian tube is viewed. This is a case of endometrioid adenocarcinoma of the ovary arising from endometriosis, occurring synchronously in eutopic endometrium. There is agreement on the risk factors of malignant transformation of endometriosis which should assist in clinical vigilance and screening of ovarian cancer associated with endometriosis. Although most ovarian malignancies require aggressive therapy, endometriosis-associated ovarian cancer appears to be less aggressive, is diagnosed early and has a better prognosis and overall survival.
Introduction
Malignant transformation of endometriosis is a rare complication, and 70% of cases are ovarian. Extra-ovarian sites include rectovaginal space, bladder, colorectal, vagina, uterosacral ligaments, umbilicus, fallopian tube and cervix.
This transformation was documented by Sampson in 1925, occurring in the ovary. Sampson described three essential criteria for carcinoma arising in the background of endometriosis. A fourth criterion was added by Scott in 1953 (Table 1) . 1 The incidence of malignant transformation of endometriosis is 0.9%. The risk factors include prolonged oestrogen exposure following surgery for endometriosis, endometriosis diagnosed at an early age and endometriosis associated with infertility. 1, 2 The most common histological subtypes are endometrioid adenocarcinoma (EC) and clear-cell carcinoma (CCC). [1] [2] [3] [4] Concurrent endometrial pathology is present in 32% cases of malignant transformation of endometriosis.
Synchronous malignancies are second malignancies occurring either simultaneously or within 6 months after the diagnosis of the first malignancy. The criteria used for the diagnosis of synchronous, double primary malignancy are described in Table 2 . 2, 3 The occurrence of synchronous tumours is not fully elucidated. Factors responsible could be genetic susceptibility, immune susceptibility and exposure to carcinogens. 3 In this case, exposure to oestrogen could hypothetically advance atypical cells in the susceptible patient.
The risk factors considered to predispose patients with endometriosis and place them at high risk for malignant transformation are as follows: long-standing endometriosis, endometriosis diagnosed at an early age, endometriosis associated with infertility, patients with an enlarging endometrioma and endometriosis diagnosed at a perimenopausal stage. [4] [5] [6] [7] [8] 
Case description
A 36-year-old nulliparous woman with a long-standing history of endometriosis presented with recurrence of pain and dysmenorrhoea. She also had a cervical myoma. She had undergone endometriosis surgery 4 years prior to alleviate pain and dysmenorrhoea. Her symptoms subsided post-surgery.
She was on oral contraceptive and had no desire to conceive. She had no medical co-morbidities and her cervical cytology was normal. There was no family history of endometriosis or cancer.
A normal-sized uterus, an enlarged cervix and a left ovarian cyst were found. A transvaginal ultrasound confirmed cervical myoma and left ovarian cyst suggestive of endometrioma. She gave consent for hysteroscopy and laparoscopy to excise endometriosis and cervical myoma.
An examination under anaesthesia (EUA) revealed an enlarged cervix with tumour-like tissue extruding from the endocervix. A biopsy of the endocervix was taken. The hysteroscopy was stopped.
During laparoscopy, there was suspicion of malignancy on the left ovary. Biopsies were taken from the pouch of Douglas, the left tube and ovary, the left ovarian fossa, the right tube and ovary, uterosacral ligaments. No lymph node biopsy was undertaken.
The histopathology revealed Grade 1 EC of the endocervix. This tumour was positive for oestrogen receptor (ER) and progesterone receptor (PR). The tumour was an endometrial primary extending into the endocervix. The left ovary had Grade 1 EC. Importantly, the left ovarian fossa had atypical endometriosis.
Oncologists took over management. A magnetic resonance imaging (MRI) of the pelvis with contrast was done.
There was a cervical mass 54 mm in diameter with infiltration into the endocervix and stromal extension. There were findings of early parametria extension and sub-centimetre external iliac chain lymph nodes.
After investigations, oncologists performed a bilateral salpingo-oophorectomy (BSO) and omental biopsies. The combination of endometriosis, malignancy and cervical myoma was perceived to place the patient at risk of prolonged surgery with haemorrhage.
The histopathology of the left ovary revealed a Grade 2 EC arising from the background of endometriosis ( Figure 1 ). The tumours were ER and PR positive. The right ovary had focal endometriosis and the omentum was free of tumour.
Post-surgery, three courses of gonapeptyl, and chemotherapy, Carboplatinum and Paclitaxel were administered. After 4 months, a repeated MRI showed significant decrease in myoma with no adenopathy or ascites.
A total abdominal hysterectomy was performed 5 months later. Histopathology showed Grade 1 EC of the endometrium.
Discussion

Characteristics shared by endometriosis and malignancy
Atypical endometriosis represents the transition from benign endometriosis to malignancy. Similar to endometrium, studies have documented the presence of hyperplasia and cytological atypia in endometriosis confirming that atypical endometriosis is a precursor to malignancy. 4 Both entities are found in local and distant tissues. They attach to other tissues, invading and damaging them. They exhibit recurrence, unregulated cell proliferation and oestrogen-dependent growth. They evade apoptosis, have stem-cell like ability, angiogenic potential and intrinsic self-regulation of their rate of proliferation. [4] [5] [6] Inflammation is the hallmark of endometriosis. The peritoneal fluid around endometriosis has high levels of macrophages, cytokines and growth factors (GFs). Table 2 . Warren and Gates' criteria for diagnosis of double primary malignancies.
1. Histological confirmation in both the index and secondary tumours 2. There should be at least 2 cm of normal mucosa between the tumours 3. Probability of one being the metastasis of the other must be excluded Table 1 . Sampson's and Scott's criteria for carcinoma arising in the background of endometriosis.
1. The carcinoma and the endometriosis must occur in the same organ 2. The carcinoma must arise from the same tissue and not invading from another source 3. There must be presence of tissue resembling ovarian stroma surrounding characteristic epithelial glands 4. There must be a morphologic demonstration of benign endometriosis that is microscopically contiguous with the malignant tissue
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Inflammation promotes tumorigenesis by producing vascular endothelial growth factor (VEGF) that causes invasion and plays a role in tumour survival. VEGF is detected in most samples of endometriosis-associated ovarian cancer.
Macrophages produce methylmetalloproteinase-9, (MMP-9), critical in breaking down extracellular matrix. The same genes that impart macrophages with the ability to degrade extracellular matrix are induced in stromal cells through the tumour necrosis factor alpha (TNF-α). This activates the trophic effect of stromal cells in an attempt to replace damaged tissue.
Through repeated insults, stromal cells can progress to malignancy. Such macrophages are known as tissue-activated macrophages (TAMs), which antagonise T-cellmediated immunity by producing immunosuppressive substances. 4 Macrophages also produce reactive oxygen species (ROS) that induce damage and mutations. The production of cytotoxic ROS is further contributed by the Fenton reaction, the binding of heme to peroxide that causes further biologic damage. 5 T-lymphocyte and B-lymphocyte abnormalities, polyclonal B-lymphocyte activation and altered apoptosis are mediators in malignant transformation. The peritoneal fluid surrounding endometriosis has lymphocytes that kill tumour cells (natural killer (NK) cells) and has reduced cytotoxicity. T lymphocytes and macrophages are increased and activated, yet they do not clear endometriosis.
Apoptosis is regulated by two proteins: B-cell lymphoma 2 (BCL-2) and protein 53 (p53). These proteins differ in their level of expression between benign and malignant disease. While BCL-2 is anti-apoptotic, p53 signals apoptosis in case of major DNA damage.
BCL-2 is upregulated in endometriosis, preventing cells from becoming irreversibly committed to apoptosis, suggesting that its anti-apoptotic activity may be one of the factors that promote malignant transformation. P53 mutation causes over-expression of non-functional p53, which accumulates within the nuclei of cells, interferes with its signalling function, thereby promoting further DNA damage. 5 Loss of heterozygosity (LOH) indicates regions of tumour suppressor gene inactivation, which is central to development of malignant tumours. Studies indicate LOH in endometriosis adjacent to or contiguous to ovarian carcinoma. These common genetic alterations indicate a genetic transition spectrum between endometriosis and cancer. 6 Mutation and LOH of the tumour suppressor gene PTEN occur in endometrial and ovarian cancer. Mutations in the PTEN gene are identified in 20% of endometriomas, 20% of EC and 8.3% of CCC. This suggests that PTEN inactivation may be an early event in the malignant transformation of endometriosis. Another tumour suppressor gene, the human mutL homolog 1 (hMLH1), encodes for an enzyme involved with intrinsic cellular DNA mismatch repair. This is hypermethylated in atypical endometriosis and stage 4 endometriosis. Hypermethylation leads to silencing of hMLH1. This silencing is an early marker of malignant transformation of endometriosis. 6 Studies have identified 'AT-rich interactive domain 1A (ARID1A)', a tumour suppressor gene mutation, in 30% cases of EC and 46% cases of CCC. The protein encoded by ARID1A is a key component in chromatin remodelling complex, involved in regulating cellular processes such as development, differentiation, proliferation, DNA repair and tumour suppression. These findings provide evidence for the inactivation of ARID1A in the development of EC and CCC associated with endometriosis. 7 Aromatase cytochrome P450 (P450arom), an enzyme responsible for oestrogen biosynthesis, is expressed in glandular epithelium of endometriosis. This pathogenic expression of P450arom triggers constitutive synthesis of oestrogen. The increased levels of oestrogen stimulate cyclo-oxygenase-2 production, which in turn increases prostaglandin E production. This further stimulates P450arom activity, contributing to more constitutive production of oestrogen. 7, 8 Progesterone is a natural antagonist of oestrogen. A reduction in expression of PR due to gene polymorphism is observed in endometriosis and ovarian cancer. 5, 8 This causes relative progesterone resistance within endometriosis and leads to further escalation of the action of oestrogen. This explains why some patients with endometriosis fail to respond to treatment with progestins.
The role of the fallopian tube
The fallopian tube is a conduit between the endometrium and the peritoneum. Retrograde menstruation enables the endometrium to implant and invade organs and tissues. This inflammation leads to establishment of endometriosis. Likewise, in ovarian cancer, the fallopian tube enables the ascension of endometrium and mediators of inflammation. 9 A new paradigm for the pathogenesis of ovarian cancer divides epithelial ovarian carcinoma into type 1 and type 2 tumours. Type 1 tumours are low-grade serous EC, CCC, mucinous and transitional carcinomas. They arise from endometrial tissue deposited onto ovarian surface via retrograde menstruation. They are genetically indolent, present early and characterised by PTEN and ARID1A mutations.
Type 2 tumours are high-grade serous EC, malignant mixed mesodermal tumours (MMMTs) and undifferentiated carcinomas. They arise from epithelium of the fimbriae in 60% of cases. They are aggressive, present in advanced stage and have a high-frequency p53 mutation. 10 Thus, both type 1 and type 2 tumours develop independently along different molecular pathways outside the ovary involving it secondarily.
Conclusion
There are no clinical guidelines for screening and detection of endometriosis-associated carcinoma (EAC). Documentation and systematic follow-up of high-risk patients are advocated.
Where fertility is not desired, high-risk patients as described above should be counselled to consider surgical removal of the endometrioma or bilateral salpingectomy. 10 The patient had a synchronous primary in the ovary and the endometrium. The endometrial primary presenting in the background of a myoma made it challenging for an optimal surgical procedure. She received two courses of chemotherapy after 4 months.
The left ovary was a FIGO stage 2B. The endometrium was a FIGO stage 1B. This was a primary tumour suggested by immunohistochemistry, WT1-negative and ER/ PR-positive status.
An early-stage EC, Grade 1, stage 1 has a 100% 5-to 10-year survival rate. The 5-year survival rate of all patients with ER-positive EAC with early diagnosis is 82%. 10 The patient is surviving well, followed up regularly by the oncologists.
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